Jin Billy Li

1 month ago | nature.com | Ying Cheng |Jun Liao |Jordi Rodon |Yongsheng Li |Yun Fan |Jin Billy Li | +1 more

AbstractTrophoblast cell-surface antigen 2 (TROP2)-directed antibody–drug conjugate (ADC) is a promising anticancer agent that has shown remarkable efficacy in several malignancies. However, in lung cancer, two phase 3 trials on TROP2-ADCs in unselected patients with advanced non-small-cell lung cancer (NSCLC) have both failed. Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC.

Nov 22, 2024 | science.org | Jacki E. Heraud-Farlow |Scott Taylor |Alistair M. Chalk |Shi-Bin Hu |Ankita Goradia |Tao Lin Sun | +8 more

Aug 21, 2024 | cell.com | Jin Billy Li |Dan Cao |Wenlu Li

Highlights Intracranial neural recordings have revealed the distinct roles of various medial temporal lobe (MTL) regions in working memory (WM). MTL regions exhibit specific interactions both internally and with the neocortex, engaging in distinct oscillatory patterns across various phases of WM. Incorporating the MTL into working memory models deepens our understanding of the intricate neural mechanisms that underlie WM.

May 31, 2024 | nature.com | Pantelitsa Dimitriou |Jin Billy Li |William Jamieson |Johannes Schneider |Oliver Kieran Castell

AbstractDroplet Interface Bilayers (DIBs) constitute a commonly used model of artificial membranes for synthetic biology research applications. However, their practical use is often limited by their requirement to be surrounded by oil. Here we demonstrate in-situ bilayer manipulation of submillimeter, hydrogel-encapsulated droplet interface bilayers (eDIBs). Monolithic, Cyclic Olefin Copolymer/Nylon 3D-printed microfluidic devices facilitated the eDIB formation through high-order emulsification.

Feb 1, 2024 | nature.com | Jin Billy Li |Zhendong Chen

AbstractAlthough antiprogrammed death 1 antibody plus chemotherapy has recently been approved for first-line esophageal squamous cell carcinoma (ESCC), antiprogrammed death-ligand 1 antibody may offer another combination option in this setting. In this multicenter, randomized, double-blinded phase 3 trial a total of 540 adults (aged 18–75 years) with unresectable, locally advanced, recurrent or metastatic ESCC and who had not received systemic treatment were enrolled.